logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Safety of hepatitis E vaccine in pregnancy: an emulated target trial following a mass reactive vaccination campaign in Bentiu internally displaced persons camp, South Sudan

Nesbitt RC, Azman AS, Asilaza VK, Edwards JK, Gitahi P,  et al.
2024-11-01 • Lancet Global Health
2024-11-01 • Lancet Global Health
Conference Material
|
Slide Presentation

Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan

Nesbitt R, Azman AS, Asilaza VK, Edwards JK, Nkemenang P,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract

Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan

Nesbitt R, Azman AS, Asilaza VK, Edwards JK, Nkemenang P,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION

Hepatitis E causes high mortality among pregnant women, with case fatality risks over 30% and adverse fetal outcomes. There is an evidence gap on the safety of the ...

Journal Article
|
Research

Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan

Nesbitt RC, Asilaza VK, Gignoux EM, Koyuncu A, Gitahi P,  et al.
2024-01-22 • PLOS Neglected Tropical Diseases
2024-01-22 • PLOS Neglected Tropical Diseases

INTRODUCTION

Hepatitis E (HEV) genotypes 1 and 2 are the common cause of jaundice and acute viral hepatitis that can cause large-scale outbreaks. HEV infection...

Conference Material
|
Abstract

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
A three-dose recombinant vaccine against hepatitis E, Hecolin, has been licensed for use in China since 2011. While not recommended for routine use due to lack of eviden...
Conference Material
|
Poster

Vaccination coverage and adverse events following immunisation after the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Slide Presentation

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Video

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Asilaza VK
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023